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Introduction:
Heart failure is a set of complex clinical syndromes characterized by impaired cardiac,
vascular, and renal function, diminished exercise tolerance, a high incidence of
ventricular arrhythmias, and a shortened life expectancy. Heart failure is the only
cardiovascular disease diagnosis increasing in prevalence in the United States. Every
year 500,000 patients are diagnosed with heart failure, and currently approximately
5,000,000 Americans are afflicted with this condition.1. Heart failure is the most
common reason for admission to an American hospital among adults over the age of 65,
with a readmission rate of 44% within 6 months.2

Congestive Heart Failure (CHF), the terminal manifestation of various heart diseases,
represents the most frequent cause of morbidity and mortality in patients aged 65 years
and older. Cognitive impairment (CI) is very prevalent in the aging and several clinical
trials have demonstrated a high association between cardiovascular diseases, particularly
CHF, and cognitive deterioration. The underlying mechanism for cognitive impairment is
still unclear but appears to be related to impaired cerebral hypoperfusion and flow
regulation. There appears to be selective cognitive impairment of verbal memory and
attention domains.

Cognitive dysfunction and heart failure:
CHF has been proposed as a possible cause of cognitive dysfunction since 1977. Initial
studies demonstrated that hypotension and congestive heart failure are risk factors for

dementia in elderly people. Roman (1987) reported that reduction of cerebral blood flow
may precede cognitive deterioration associated with typical, diffuse, cerebral
periventricular white matter changes (leucoaraiosis).3 These alterations appeared to be
related with low cardiac output. Acanforo et al. (1993) confirmed that luecoaraiosis is
significantly related to age, congestive heart failure, and hypotension (systolic blood
pressure <130mmHg).4 Furthermore, rather than studying the association of dementia in
relation to cardiovascular diseases, Gorkin et al., introduced neuropsychological tests to
evaluate the quality of life in patients with left ventricular dysfunction (SOLVD study).5
The authors concluded that patients with NYHA I obtained better results on tests
assessing sustained attention than patients with NYHA Class II and III.

These earlier studies established an association between heart failure and cognitive
deterioration but clinical trials detailing this association were needed. The CHF Italian
Study I, a multicenter study on hospitalized elderly CHF patients, included a brief
screening of cognitive abilities. The Mini Mental State Examination (MMSE) was used
for the evaluation of cognitive function. The presence of congestive heart failure was
associated with a significant decrease of MMSE scores: mean MMSE score after
statistical adjustment for confounding variables (age, BP, previous CVA’s and education)
was about one point lower in patients with congestive heart failure in contrast to elderly
patients affected by heart disease but without congestive heart failure.4 This has been
duplicated in cognitively impaired patients with end-stage heart failure awaiting
transplantation. There is a significant improvement in cognitive function, measured with
the MMSE, after undergoing cardiac transplantation.6

The prevalence of CHF in cognitively impaired subjects is high and the risk of CI is 1.96fold greater in subjects with CHF.7 This was examined in a cross-sectional study of 1072
subjects aged 65 years and older in Southern Italy. A MMSE score <24 indicated
cognitive impairment. The prevalence of CHF in subjects with an MMSE score of <24
and >24 was 20.2% and 4.6%, respectively (p<.001). 7 Logistic regression analysis
showed that CHF was independently associated with CI by age, sex, educational level,
GDS, diabetes, HTN, alcohol consumption, smoking, atrial fibrillation, HR, and systolic
and diastolic BP. 3 Moreover, systolic BP correlated negatively with NYHA classes only
in subjects with cognitive impairment, whereas HR increase correlated positively with
NYHA classes only in subjects without cognitive impairment. 7 This analysis suggests
that systolic BP reduction and the lack of HR increase, related to NYHA classes, might
characterize cognitively impaired subjects with CHF. Since there was no difference in
CHF therapy between subjects with MMSE <24 and those with MMSE >24, the lack of
HR increase could not be explained by beta blocker therapy.

Verbal memory and attention appear to be the domains of cognitive impairment most
affected in CHF patients. The severity of cognitive impairment parallels that of CHF as
expressed by NYHA class. Incalzi et al. further delineated the effect of CHF on verbal
memory, specifically primary (short term memory) and secondary (long term) memory.8
In addition, they analyzed the mechanisms of memory impairment in different stages of
CHF. Performance on some verbal memory indexes (Recency, Rey’s immediate and
delayed recall, Learning efficiency) progressively decreased from NYHA II to IV. 8 Rate

of forgetting was uniformly high across NYHA II-IV which suggests that memory
dysfunction complicating CHF has some specific features. 8 The prevalent impairment of
the Recency index, which assesses primary memory, suggests that CHF affects mainly
the component of memory which declines less with aging. 8 Further, the MMSE actually
has poor sensitivity and specificity versus primary or secondary memory dysfunction. 5
Therefore, a deficit of both primary and secondary memory is relatively common in CHF
but cannot accurately be recognized by a screening neuropsychological test. 8

Mechanism of cognitive dysfunction and heart failure:
Cerebral hypoperfusion may be the common pathophysiologic mechanism by which CHF
patients develop dementia. Since blood pressure is usually adequately maintained in
patients with LV dysfunction, low cardiac output, as opposed to systemic hypotension, is
likely the primary etiology of reduced cerebral blood flow.9

In addition, cerebral reactivity is impaired in patients with cardiac failure and a decline in
cardiac function correlates with a reduction in cerebrovascular reactivity. Georgiadis et
al. measured end-tidal CO2 values during normocapnia and hypercapnia induction as
well as peak CO2 values and corresponding mean blood flow velocities in the right and
left middle cerebral arteries.10 Cerebrovascular reactivity (CR) was calculated using
these variables. CR was significantly higher in controls as compared to all patient groups,
and in NYHA II and III as compared to NYHA IV patients; there was no statistical
difference between class II and III patients 10 (Figure 1). In theory, a decline in cardiac
output may lead to partial recruitment of cerebrovascular reactive dilatory capacity in

patients with chronic heart failure. This decline in cerebrovascular reserve capacity could
be responsible for the cognitive dysfunction that has been observed. 10
Cerebrovascular reactivity in heart failure patients and normal controls (figure 1)
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Cerebral metabolic abnormalities have also been investigated as a potential marker of
disease severity in CHF, but their prognostic significance remains unclear. Lee et al.
investigated the prognostic value of cerebral metabolic abnormalities in 130 patients
being evaluated for cardiac transplantation.11 Occipital N-acetylaspartate was shown to
be an independent predictor of death. 11 These results suggest that an integrated
examination of both perfusion and metabolite concentrations in heart failure patients with
cognitive dysfunction may be informative. This may provide insight into a final common
biochemical pathway linking cognitive decline and heart failure progression.

Relationship between frailty, CHF, and mortality:

Cognitive impairment is just one aspect of frailty, a novel concept that is not yet well
defined in the literature. Frailty is a complex entity that encompasses a range of clinical
conditions such as limited mobility with a predilection to falls, polypharmacy,
comorbidity, low social status, nutritional impairment and cognitive impairment.12
Previous methods to grade frailty have focused only on the physical domain. A grading
system was developed that is more consistent with the complexity of frailty. The authors
used The Frailty Staging System (FSS) as an index of severity of functional impairment.
12

The FSS integrates seven core domains of functioning: disability, mobility, cognitive

function, visual function, hearing function, urinary continence and social support.
Subjects were then stratified into three classes of frailty. 12 In subjects with CHF
stratified into classes of frailty, there was a statistically significant increase in age,
comorbidity and disability and a decrease in MMSE score. 12 Significantly, KaplanMeier analysis shows that at 9 years the probability of survival progressively decreased
with frailty, increasing from 45.5% to 0 in subjects with CHF and from 62.8% to 25.9%
in those without CHF. 9 Median survival (in months) for patients with CHF in frailty
classes 1, 2 and 3 was 101.2, 72.0 and 60.0, respectively. (Figure 2). Thus, frailty
represents a new variable that independently predicts mortality in elderly CHF patients. 12

Frailty and median survival (figure 2)
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Conclusions:
As heart failure continues to be major and growing public health problem in the United
States with a significant morbidity and mortality the complex nature of this clinical
syndrome requires a multidisciplinary approach to, both deal with the devastating
consequences of the disease process, but also to create an environment for both physical
and mental rehabilitation. Cognitive impairment appears to be a relatively common and
predictable effect of CHF. It could contribute with social and behavioral problems that
decrease the compliance of CHF patients to prescribed therapy and, as a consequence,
increase the rate of hospital readmissions. The validity of the MMSE, once though to be

the ideal test for assessing cognitive impairment, needs to be readdressed. Nonetheless,
further investigation should clarify whether memory-enhancing protocols might improve
the compliance of CHF patients. The efficacy of assessing and treating low output states
by measuring cerebral reactivity and cerebral metabolites across the spectrum of heart
failure patients also needs to be elucidated in larger clinical trials. Finally, further
investigation into the concept of frailty and the relationship to congestive heart failure
and mortality is necessary in larger CHF cohort studies. Further studies are also needed
to elucidate the underlying mechanism(s) of cognitive impairment and whether memory
impairment can be prevented or slowed by properly designed training programs thereby
improving the quality of life of the patient.
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